The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...
On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district court injunction ...
The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...
On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...
The cost of prescription drugs is certain to be a hot-button issue in the coming Illinois legislative session with two separate measures making for curious bedfellows in Springfield.
The view inside a CVS pharmacy. (Photo by Lynne Terry/Oregon Capital Chronicle) In May 2025, Gov. Jared Polis signed Senate Bill 71 into law, dramatically expanding Colorado’s participation in the ...
A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements ...
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Federal regulators have greenlit eight drugmaker ...
8d
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy?
Sagebrush Health Services has filed a lawsuit in California state court accusing Amgen of unlawfully cutting off 340B discounted drug sales to its Nevada clinics and reclaiming at least US$7,000,000 ...
The trade group Pharmaceutical Research and Manufacturers of America has filed a lawsuit in federal district court to stop HHS from implementing a regulation that would allow certain healthcare ...
As the Trump administration prepares to force its Most Favored Nation price controls on drug makers, a major U.S. lobbying group is pushing for a change to drug discounts law that would necessitate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results